Silencing of PRKCSH in NSCLC cells caused decreased cell proliferation and increase in the proportion of apoptotic cells, and when combined with gefitinib both these effects were significantly enhanced (Figs. 1C and D). This evidence concerns the gene PRKCSH and non-small cell lung carcinoma.